Nothing Special   »   [go: up one dir, main page]

ECSP14028814A - Nueva forma de dosificación y formulación de abediterol - Google Patents

Nueva forma de dosificación y formulación de abediterol

Info

Publication number
ECSP14028814A
ECSP14028814A ECIEPI201428814A ECPI201428814A ECSP14028814A EC SP14028814 A ECSP14028814 A EC SP14028814A EC IEPI201428814 A ECIEPI201428814 A EC IEPI201428814A EC PI201428814 A ECPI201428814 A EC PI201428814A EC SP14028814 A ECSP14028814 A EC SP14028814A
Authority
EC
Ecuador
Prior art keywords
provides
bediterol
abediterol
dosage
formulation
Prior art date
Application number
ECIEPI201428814A
Other languages
English (en)
Inventor
Miquel Serra Gonzalo De
Ruiz Sandrine Allain
Nunez Beatriz Seoane
Original Assignee
Alexander Matthew David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317311&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14028814(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexander Matthew David filed Critical Alexander Matthew David
Publication of ECSP14028814A publication Critical patent/ECSP14028814A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención proporciona, una composición farmacéutica en forma de polvo seco para inhalación que comprende abediterol o una sal farmacéuticamente aceptable del mismo en mezcla con un excipiente inerte farmacéuticamente aceptable, que proporciona al ser inhalada una dosis equivalente a una dosis nominal medida de aproximadamente 1,25 o aproximadamente 2,5 de base libre abediterol administrada con el inhalador Genuair®. La presente invención también proporciona dicha composición farmacéutica para uso en el tratamiento de una enfermedad respiratoria tal como asma y enfermedad pulmonar obstructiva crónica EPOC.
ECIEPI201428814A 2012-05-31 2014-11-26 Nueva forma de dosificación y formulación de abediterol ECSP14028814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382221.5A EP2668941A1 (en) 2012-05-31 2012-05-31 Novel dosage form and formulation of abediterol
US201261660003P 2012-06-15 2012-06-15

Publications (1)

Publication Number Publication Date
ECSP14028814A true ECSP14028814A (es) 2015-12-31

Family

ID=46317311

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201428814A ECSP14028814A (es) 2012-05-31 2014-11-26 Nueva forma de dosificación y formulación de abediterol

Country Status (29)

Country Link
US (2) US20150140099A1 (es)
EP (2) EP2668941A1 (es)
JP (1) JP6272836B2 (es)
KR (2) KR20180104197A (es)
CN (1) CN104394852A (es)
AR (1) AR091233A1 (es)
AU (1) AU2013269565B2 (es)
BR (1) BR112014029735A2 (es)
CA (1) CA2871358C (es)
CL (1) CL2014003286A1 (es)
CO (1) CO7141434A2 (es)
CR (1) CR20140540A (es)
DO (1) DOP2014000271A (es)
EA (1) EA201401354A1 (es)
EC (1) ECSP14028814A (es)
HK (1) HK1203149A1 (es)
IL (1) IL235831B (es)
IN (1) IN2014DN08672A (es)
MX (1) MX2014014350A (es)
MY (1) MY184654A (es)
NI (1) NI201400139A (es)
NZ (1) NZ701261A (es)
PE (1) PE20150171A1 (es)
PH (1) PH12014502662A1 (es)
SG (3) SG10201913424SA (es)
TW (1) TWI610690B (es)
UY (1) UY34838A (es)
WO (1) WO2013178742A1 (es)
ZA (1) ZA201407405B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
US20150224197A1 (en) * 2012-07-05 2015-08-13 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation compositions
MA40027A (fr) * 2014-06-18 2015-12-23 Cipla Ltd Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
US11938277B2 (en) 2018-05-22 2024-03-26 C. R. Bard, Inc. Catheterization system and methods for use thereof
WO2020033752A1 (en) 2018-08-10 2020-02-13 C. R. Bard, Inc. Automated urine-output-measurement systems and methods thereof
US12083261B2 (en) 2020-06-05 2024-09-10 C. R. Bard, Inc. Automated fluid output monitoring
US12055249B2 (en) 2020-07-21 2024-08-06 C. R. Bard, Inc. Automatic fluid flow system with retractable connection
US11931151B2 (en) 2020-12-22 2024-03-19 C. R. Bard, Inc. Automated urinary output measuring system

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT7920688V0 (it) 1979-02-05 1979-02-05 Chiesi Paolo Parma Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore.
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
FI69963C (fi) 1984-10-04 1986-09-12 Orion Yhtymae Oy Doseringsanordning
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
IT1237118B (it) 1989-10-27 1993-05-18 Miat Spa Inalatore multidose per farmaci in polvere.
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9015522D0 (en) 1990-07-13 1990-08-29 Braithwaite Philip W Inhaler
WO1992003175A1 (en) 1990-08-11 1992-03-05 Fisons Plc Inhalation device
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
EP0640354B1 (en) 1990-09-26 2001-12-05 Pharmachemie B.V. Whirl chamber powder inhaler
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE4239402A1 (de) 1992-11-24 1994-05-26 Bayer Ag Pulverinhalator
MY115140A (en) 1992-12-18 2003-04-30 Schering Corp Inhaler for powdered medications
EP0837710B1 (en) 1995-06-21 2001-11-28 ASTA Medica Aktiengesellschaft Pharmaceutical powder cartridge with integrated metering device and inhaler for powdered medicaments
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2211344B1 (es) 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
MXPA06003376A (es) * 2003-09-26 2006-06-08 Schering Corp Tratamiento de enfermedad pulmonar.
ES2232306B1 (es) 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ATE481996T1 (de) 2004-07-16 2010-10-15 Almirall Sa Inhalator für die abgabe von pharmzeutischen pulver, und ein pulverkassette zur verwendung mit diesem inhalator
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
EP2100598A1 (en) * 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
EP2221297A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases
EP2221055A1 (en) * 2009-02-18 2010-08-25 Almirall, S.A. 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function

Also Published As

Publication number Publication date
PH12014502662A1 (en) 2015-02-02
CO7141434A2 (es) 2014-12-12
MY184654A (en) 2021-04-14
TWI610690B (zh) 2018-01-11
IL235831A0 (en) 2015-01-29
CL2014003286A1 (es) 2015-02-20
MX2014014350A (es) 2015-03-03
AR091233A1 (es) 2015-01-21
US20150140099A1 (en) 2015-05-21
CA2871358C (en) 2020-09-29
UY34838A (es) 2014-03-31
WO2013178742A1 (en) 2013-12-05
TW201347789A (zh) 2013-12-01
US20160303108A1 (en) 2016-10-20
EA201401354A1 (ru) 2015-05-29
JP2015519356A (ja) 2015-07-09
AU2013269565A1 (en) 2014-10-30
CN104394852A (zh) 2015-03-04
DOP2014000271A (es) 2015-02-27
NI201400139A (es) 2015-12-10
KR20150018526A (ko) 2015-02-23
KR20180104197A (ko) 2018-09-19
EP2854771A1 (en) 2015-04-08
BR112014029735A2 (pt) 2017-06-27
SG10201609119VA (en) 2016-12-29
PE20150171A1 (es) 2015-01-31
CA2871358A1 (en) 2013-12-05
JP6272836B2 (ja) 2018-01-31
AU2013269565B2 (en) 2017-07-20
IN2014DN08672A (es) 2015-05-22
CR20140540A (es) 2015-01-16
SG10201913424SA (en) 2020-03-30
SG11201407110QA (en) 2014-12-30
IL235831B (en) 2020-09-30
EP2668941A1 (en) 2013-12-04
ZA201407405B (en) 2015-11-25
NZ701261A (en) 2016-08-26
HK1203149A1 (en) 2015-10-23

Similar Documents

Publication Publication Date Title
ECSP14028814A (es) Nueva forma de dosificación y formulación de abediterol
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
CY1120605T1 (el) Παρασκευασμα ξηρης σκονης που περιλαμβανει εναν αναστολεα φωσφοδιεστερασης
AR067639A1 (es) Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente
CO6640319A2 (es) Formulación en polvo seca que comprende una droga antimuscarínica
UA101652C2 (uk) Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
EA201590019A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы
AR100368A1 (es) Tratamiento de trastornos respiratorios
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
MY187442A (en) A pharmaceutical composition containing budesonide and formoterol
AR098867A1 (es) Composición farmacéutica en polvo seco para inhalación
BR112014003907A2 (pt) método para preparar inalador pulverizado de dose medida para tratar doença respiratória
CO2017004512A2 (es) Composición farmacéutica que contiene budesonida y formoterol
BR112014028864A2 (pt) dosagem e formulação
TH1401007107A (th) รูปฟอร์มขนาดใช้ยา และ สูตรผสมใหม่ของเอบีไดเทอรอล